

# Zoi Karoulia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4776700/publications.pdf>

Version: 2024-02-01

8  
papers

716  
citations

1307594

7  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

1595  
citing authors

#	ARTICLE	IF	CITATIONS
1	New perspectives for targeting RAF kinase in human cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 676-691.	28.4	285
2	SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. <i>Cell Reports</i> , 2019, 26, 65-78.e5.	6.4	146
3	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. <i>Cancer Cell</i> , 2016, 30, 485-498.	16.8	130
4	RAF/MEK/extracellular signalâ€related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. <i>Journal of Experimental Medicine</i> , 2018, 215, 319-336.	8.5	58
5	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , 2021, 27, 851-861.	30.7	38
6	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	9.4	30
7	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. <i>Nature Cancer</i> , 2021, 2, 429-443.	13.2	29
8	Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6. , 2021, , .		0